INSULIN GLARGINE MARKET ANALYSIS

Market Size and Trends

Global insulin glargine market is estimated to be valued at USD 5.45 Bn in 2024 and is expected to reach USD 8.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

To learn more about this report, request a free sample copy

Global insulin glargine market is expected to witness a positive growth trend over the forecast period. The patent expiration of major insulin brands coupled with the introduction of affordable biosimilar insulin glargine products will boost market volume. Furthermore, technological advancements in drug delivery devices such as wearable and smart insulin pens and pumps will support this trend. However, stringent regulations for the approval of insulin products may slightly hamper market growth during the forecast years.

Rise in prevalence of diabetes

Increasing incidence of diabetes around the world is expected to augment growth of the global insulin glargine market over the forecast period. Like other types of insulin, insulin glargine (a long-acting medical insulin) is used to keep the blood sugar level close to normal. According to the International Diabetes Federation (IDF) Report in 2021, , around 537 million adults (20-79 years) are living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Increasing use of insulin glargine across the globe is expected to boost the growth of the global insulin glargine market during the forecast period. Insulin glargine is a self-injectable solution that is used to control high blood sugar (hyperglycemia) in individuals with type 1 and 2 diabetes, and therefore, the use of insulin glargine has increased worldwide. In November 2021, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of SEMGLEE (insulin glargine-yfgn) injection, and Insulin Glargine (insulin glargine-yfgn) injection to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

To learn more about this report, request a free sample copy

High cost of insulin glargine is expected to hamper the growth of the global insulin glargine market. For instance, Lantus (insulin glargine injection) is the prime example of an expensive insulin, averaging around US$ 274 per month. The cost for Lantus subcutaneous solution (100 units/mL) is around US$ 308 for a supply of 10 milliliters. However, the monthly cost of the insulin depends on the dosage prescribed. Introduction of or availability of insulin biosimilars is expected to hinder growth of the insulin glargine market. For instance, biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Furthermore, biosimilar insulins are cheaper as compared to original products.

Market Opportunities: Increase in awareness among people about diabetes management

Diabetes affects millions worldwide and its proper management is crucial. As awareness about diabetes and the importance of managing blood sugar levels rises globally, it presents a major growth opportunity for the Insulin Glargine market. More people are recognizing the need to monitor their glucose and seek treatment options like Glargine to control spikes and maintain healthy levels. This increased awareness has been driven by health initiatives by non-profit organizations like the International Diabetes Federation to educate on diabetes prevention and care.

To learn more about this report, request a free sample copy

Type segment is sub-segmented into lantus, basaglar, toujeo, soliqua/suliqua, and others. Lantus segment is anticipated to hold 42.7% of the market share in 2024. Being the first long-acting insulin analogue launched in the market, Lantus has created deep brand recognition among patients and physicians over the decades. Its effectiveness in controlling blood sugar levels throughout the day with just one dose has made it the go-to option for many diabetes patients. The availability of Lantus in prefilled pen devices has also significantly improved adherence and usability compared to vials.

While Basaglar and Toujeo offer possible cost savings as biosimilars and newer formulations respectively, patients remain reluctant to switch from the trusted Lantus brand that has been stabilizing their blood sugar for many years. Physicians are also cautious about recommending alternates without a strong clinical reason, given the sensitive nature of diabetes management. Unless newer entrants can prove superior outcomes, Lantus is likely to retain its dominant share through strong patient loyalty and preferences shaped over the long brand lifecycle.

Insights, By Diabetes Type: Increasing prevalence of Type 2 Diabetes

Diabetes type segment is sub-segmented into Type 2 Diabetes and Type 1 Diabetes. Type 2 Diabetes segment contributes the highest share of the insulin glargine market and is projected to hold 84.8% of the market share in 2024. Individuals with Type 2 diabetes can often control their condition through oral medications and lifestyle changes in the initial stages. However, as the disease progresses, insulin supplementation becomes inevitable for many. Type 2 diabetes exerts its impact on numerous vital organs, encompassing the heart, blood vessels, nerves, eyes, and kidneys. Furthermore, the risk factors associated with diabetes are concurrent risk factors for various other severe illnesses. Effective management of diabetes and regulation of blood sugar levels can substantially diminish the likelihood of experiencing these complications as well as mitigate the risk of other medical conditions. Although type 2 diabetes primarily manifests in individuals over the age of 45, there is a notable trend of its occurrence among children, adolescents, and young adults.

Insights, By Distribution Channel: Convenience drives retail pharmacies growth

Distribution channel segment is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment contribute the highest share of the insulin glargine market and is projected to hold 39.2% of the market share in 2024. Retail pharmacies are increasingly becoming the primary source for filling insulin prescriptions among Type 2 patients due to convenience. Busy individuals find it easier to pick up their insulin supplies from local pharmacies along with other medications on their weekly visits. This saves them time compared to traveling to hospitals or specialty pharmacies. Retail chains also stay open for longer hours with many locations, enhancing accessibility. From the patient perspective, minimizing risk of complications from improper insulin storage or administration is a priority. Retail pharmacies provide expert counseling and supervision during the initialization period to ensure safe use. This plays a big role in driving adherence to insulin therapy, reducing health hazards and disease progression over the long-run.

Regional Insights

To learn more about this report, request a free sample copy

The North American region currently dominates the global insulin glargine market and is projected to hold 43.7% of the market share in 2024. The key factor contributing to its leadership position is the large diabetic population in the U.S. With nearly 1 in 10 Americans suffering from diabetes, there is considerable demand for long-acting insulin treatments like insulin glargine. Furthermore, North America is home to leading insulin manufacturers such as Sanofi, Eli Lilly, and Novo Nordisk, who have established robust production and distribution infrastructure to serve the regional market. These companies have strongly promoted insulin glargine products like Lantus and Basaglar through marketing campaigns targeted towards patients and physicians. This has raised awareness and uptake of insulin glargine as an effective treatment option for diabetes patients requiring basal insulin.

The Asia Pacific region, especially China and India, is poised to be the fastest-growing market for insulin glargine. This growth can be attributed to several socio-economic factors. Rapid urbanization, rising income levels and growing geriatric population in Asia Pacific countries are contributing to a rising prevalence of diabetes in the region. Additionally, improving healthcare access and coverage is enabling more diabetic patients to opt for patented medications like insulin glargine. Their affordable pricing makes glargine therapy more accessible for Asian patients. Furthermore, regional trade agreements are facilitating greater market access and product flow within Asia Pacific nations. This will encourage regional suppliers to invest more in manufacturing, distribution and marketing of insulin glargine products across the fast-growing Asia Pacific healthcare markets.

Market Report Scope

Key Developments

• In March 2023, Sanofi, a pharmaceutical and healthcare company, stated that it will reduce the list price of Lantus (insulin glargine injection) 100 Units/mL, its most commonly prescribed insulin in the U.S., by 78%. The company will also set a USD 35 out-of-pocket cost cap for Lantus for all patients with commercial insurance, demonstrating its long-standing commitment to providing affordable access to medicines.
• In July 2021, Biocon Biologics Ltd., a biopharmaceutical company and Viatris Inc., a global pharmaceutical company announced that Semglee (insulin glargine-yfgn injectable) had been approved by the United States Food and Drug Administration (FDA) as the first interchangeable biosimilar under the 351(k) regulatory pathway.
• In August 2020, Mylan N.V. (acquired by Viatris Inc.) and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, which is approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

*Definition: The Insulin Glargine Market consists of the manufacturing and sales of the long-acting insulin analog insulin glargine, which is used for the treatment of diabetes mellitus. Insulin glargine is a recombinant DNA human insulin analog that is identical to human insulin except for some changes in the amino acid sequence. It has a duration of action of over 24 hours, making it suitable for once-daily administration. The global insulin glargine market has seen significant growth in recent years due to the rise in diabetic population

Market Segmentation

•  Type Insights (Revenue, USD BN, 2019 - 2031)
  • Lantus
  • Basaglar
  • Toujeo
  • Soliqua/Suliqua
  • Others
•  Diabetes Type Insights (Revenue, USD BN, 2019 - 2031)
  • Type 2 Diabetes
  • Type 1 Diabetes
•  Distribution Channel Insights (Revenue, USD BN, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD BN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Sanofi
  • Biocon
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Gan & Lee
  • Kalbe Pharma
  • Polus Biopharm
  • Samsung Bioepis
  • Wockhardt
  • Novo Nordisk AS
  • Julphar
  • Viatris Inc.